The U.S. Food and Drug Administration (FDA) has approved a prefilled syringe format for Ani Pharmaceuticals’ purified Cortrophin Gel…
Articles by Andrea Lobo, PhD
Disability progression independent of relapse activity, or PIRA, in the earliest stages of relapsing-remitting multiple sclerosis (RRMS) is associated…
Note: This story was updated March 6, 2025, to clarify the specific disability measures and results assessed in each…
A new model that combines genetic and symptom-based risk scores to predict the development of multiple sclerosis (MS) could…
Tiziana Life Sciences is partnering with a contract development and manufacturing organization with expertise in intranasal drugs to accelerate the…
Four more people with nonactive secondary progressive multiple sclerosis (SPMS) have received foralumab nasal spray — Tiziana Life…
Using Ocrevus (ocrelizumab) as a first-line treatment for early-stage relapsing forms of multiple sclerosis (MS) is significantly better…
Switching from anti-CD20 medications to less effective fumarate therapies is linked to reduced healthcare visits and costs related to infections…
Enigma Biomedical has entered into an agreement with Neuraly to use its PET imaging tracer PMI04 to visualize…
Patient enrollment has been completed ahead of schedule in a Phase 2 clinical trial evaluating Contineum Therapeutics‘ PIPE-307, an…
IMP761, an experimental immunotherapy Immutep is developing for multiple sclerosis (MS) and other autoimmune conditions, has shown a…
LPX-TI641, Lapix Therapeutics‘ experimental oral therapy to restore immune system balance in people with multiple sclerosis (MS)…
An artificial intelligence (AI)-based tool called Muse aims to accelerate drug development by optimizing clinical trial patient recruitment. The tool,…
Cionic has partnered with Lovell Government Services, a veteran-owned business, to expand veterans’ access to its Neural Sleeve,…
The MS Society of Canada is hosting its annual MS Read-a-Thon, a fundraiser where children are encouraged to…
Poltreg will receive a patent in China that covers the administration of its cell-based therapy PTG-007 for multiple sclerosis…
The U.S. Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq), a subcutaneous, or under-the-skin, formulation of…
Neufit is encouraging people with multiple sclerosis (MS) to register for its upcoming MS Bootcamp, a three-day event…
Treatment with rituximab, a CD20 inhibitor used off-label for multiple sclerosis (MS) patients, can stabilize disability progression and reduce…
Treatment with the investigational BTK inhibitor tolebrutinib significantly delayed the onset of confirmed disability progression in people with nonrelapsing…
Iaso Biotherapeutics has received the green light from the U.S. Food and Drug Administration (FDA) to start clinical trials…
The National Multiple Sclerosis Society (NMSS) said it named Tim Coetzee, PhD, president and chief executive officer. Coetzee had…
Treatment with modafinil, a stimulant approved in the U.S. for treating certain sleep-related disorders, significantly reduced fatigue and improved overall…
The Australian government’s Medical Research Future Fund (MRFF) has awarded AU$2.9 million (about $1.96 million) to support a project focused…
Bit.bio, a company that creates human-derived cell products, has launched a novel product called ioAstrocytes, which provides functional…
The European Commission has approved a subcutaneous, or under-the-skin, formulation of Ocrevus (ocrelizumab) to treat adults with multiple…
Switching to one of the anti-CD20 targeting therapies Ocrevus (ocrelizumab) or rituximab may be an effective strategy for…
A large proportion of people with multiple sclerosis (MS) experience headaches as a result of their condition, and treatment…
Helius Medical Technologies said it has a booth at a meeting for multiple sclerosis (MS) professionals to showcase…
Progentos Therapeutics said it received $65 million in funding to support the development of myelin regeneration medications able to…